Stockscreener 앱 받기
1.54
10.79%
0.15
시간 외 거래:
1.51
-0.03
-1.95%
전일 마감가:
$1.39
열려 있는:
$1.35
하루 거래량:
3.33M
Relative Volume:
0.52
시가총액:
$8.21M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+54.23%
1개월 성능:
+110.96%
6개월 성능:
-99.57%
1년 성능:
+0.00%
1일 변동 폭
$1.31
$1.59
1주일 범위
$0.85
$1.89
52주 변동 폭
$0.55
$1,200.00
Polyrizon Ltd Stock (PLRZ) Company Profile
PLRZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.54 | 7.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
How Polyrizon Ltd. stock reacts to Fed policy changesFree Market Volatility Navigation Tips - jammulinksnews.com
Biotech Alert: Searches spiking for these stocks today - TipRanks
Why Did Polyrizon Plunge 11.7% Despite PL-14 Success? - AInvest
Is Polyrizon Ltd. a good long term investmentBreakthrough financial growth - Autocar Professional
Polyrizon Ltd. Stock Analysis and ForecastExceptional growth trajectory - jammulinksnews.com
Polyrizon Stock Soars 37.93% on Nasal Allergy Breakthrough - AInvest
Why Did Polyrizon Stock Soar 26.21%? - AInvest
What drives Polyrizon Ltd. stock priceDynamic investment growth - jammulinksnews.com
What analysts say about Polyrizon Ltd. stockDynamic capital growth - jammulinksnews.com
Polyrizon Skyrockets 66% Intraday—Can This Nasal Allergy Breakthrough Reshape Biotech? - AInvest
Polyrizon Skyrockets 61.93% Intraday, Is This the Dawn of a Biotech Breakthrough? - AInvest
Polyrizon stock soars after promising nasal allergy blocker test results - Investing.com India
Polyrizon Ltd. Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - MarketScreener
Polyrizon Achieves Breakthrough in Allergy Blocker Study - TipRanks
Polyrizon’s nasal allergy blocker shows promising deposition results - Investing.com Australia
Polyrizon's Nasal Barrier: A Disruptive Leap in Allergy Therapeutics? - AInvest
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study - The Manila Times
Breakthrough: New Allergy Blocker Shows 60% Success Rate in Nasal Delivery StudyMajor Step for $210M Market - Stock Titan
Polyrizon retains Nasdaq listing following hearings panel - MSN
Best Biotech Stocks To Research – July 15th - Defense World
Polyrizon Plunges 11.06% Amid Market Challenges - AInvest
Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved - Benzinga
Polyrizon Retains Nasdaq Listing Following Hearings Panel - 富途牛牛
Why Polyrizon Ltd. stock attracts strong analyst attentionFree Access to Stock Community - Newser
How Polyrizon Ltd. stock performs during market volatilitySmart Trading With Safety Margin - Newser
What makes Polyrizon Ltd. stock price move sharplyFree High-Accuracy Stock Picks - Newser
Polyrizon Ignites 65% Surge—What’s Driving the Unstoppable Rally? - AInvest
Polyrizon secures continued Nasdaq listing after panel hearing By Investing.com - Investing.com Canada
Polyrizon secures continued Nasdaq listing after panel hearing - Investing.com
Polyrizon Ltd. Secures Continued Nasdaq Listing Following Compliance Plan Implementation - Nasdaq
Polyrizon Wins Crucial Nasdaq Appeal: Inside the $15.7M Biotech's Path to Compliance - Stock Titan
Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest - MSN
Polyrizon Ltd. Announces Board Changes and Confirms Independent Directors - The Globe and Mail
Polyrizon director Omer Srugo resigns; board affirms independent members - Investing.com
Polyrizon director Omer Srugo resigns; board affirms independent members By Investing.com - Investing.com UK
Polyrizon Ltd (PLRZ) 재무 분석
Polyrizon Ltd (PLRZ)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):